Tomographic characteristics of the vitreomacular interface in diabetic macular edema

Authors

Keywords:

diabetic retinopathy, macular edema, optical coherence tomography

Abstract

Introduction: Diabetic macular edema is a common complication of diabetic retinopathy that affects central vision. Optical coherence tomography is the gold standard diagnostic tool for following and monitoring the evolution of retinal thickness, fluid presence, and vitreomacular interface characteristics.

Objective: To describe the tomographic characteristics of the vitreomacular interface and diabetic macular edema in diabetic patients.

Methods: A descriptive, cross-sectional study was conducted in 93 patients (154 eyes). Variables related to the characteristics of diabetic macular edema and changes in the vitreomacular interface were studied. Summary measures were used for qualitative variables (frequencies), and the mean and standard deviation for quantitative variables. The chi-square test of independence was used to identify associations between variables.

Results: Diabetic macular edema with foveal involvement was observed in 83.76% of eyes; 74.02% showed intraretinal cysts. The average central macular thickness was 474.7 microns, reflecting the severity of the edema. Some changes in the vitreomacular interface were present in 83.11% of eyes, the most common being epiretinal membrane (75.0%) and anomalous posterior vitreous detachment (47.6%).

Conclusions: Diabetic macular edema is characterized by a high prevalence of vitreomacular interface abnormalities; therefore, it is essential to identify the central macular thickness, the presence of cysts, hyperreflective spots, and changes in the vitreomacular interface to establish the visual prognosis of patients.

Downloads

Download data is not yet available.

References

1. Simó-Servat O, Hernández C, Simó R. Diabetic Retinopathy in the Context of Patients with Diabetes [Internet]. Ophthalmic Res. 2019; 62(4):211-7. DOI: 10.1159/000499541

2. Ting DS, Cheung GC, Wong TY. Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review [Internet]. Clin Exp Ophthalmol. 2016; 44(4):260-77. DOI: 10.1111/ceo.12696

3. Im JHB, Jin YP, Chow R, Yan P. Prevalence of diabetic macular edema based on optical coherence tomography in people with diabetes: A systematic review and meta-analysis [Internet]. Surv Ophthalmol. 2022; 67(4):1244-51. DOI: 10.101610.1016/j.survophthal.2022.01.009

4. Castillo-Otí JM, Cañal-Villanueva J, García-Unzueta MT, Galván-Manso AI, Callejas-Herrero MR, Muñoz-Cacho P. Prevalencia y factores de riesgo asociados a la retinopatía diabética en Santander. Norte de España [Internet]. Aten Primaria. 2020; 52(1):29-37. DOI: 10.1016/j.aprim.2018.10.001

5. Teo, Zhen Ling. Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis [Internet]. Ophthalmology. 2021; 128(1):1580-91. DOI: 10.1016/j.ophtha.2021.04.027

6. García Espinilla P, Arlanzón Lope A, Novo Díez DR, Llanos Ferraris S, Ortiz Toquero P, de la Iglesia Rodríguez M. Análisis de la prevalencia de la retinopatía diabética en un programa de cribado por telemedicina durante el periodo 2018 a 2023 [Internet]. Archivos de la Sociedad Española de Oftalmología. 2025; 100(7):1016. DOI: 10.1016/j.oftal.2025.02.008

7. Vivas-Giraldo José P, Bravo-Acosta Juan D. Caracterización de la retinopatía diabética en un programa de tamización en Medellín, Colombia, en el año 2018 [Internet]. Rev mex oftalmol. 2021; 95(3):118-23. DOI: 10.24875/rmo.m21000169

8. McCannel CA, Bhatti MT. The Basic and Clinical Science Course of the American Academy of Ophthalmology: The 50th Anniversary of a Unicorn Among Medical Textbooks [Internet]. JAMA Ophthalmol. 2022; 140(3):225–6. DOI: 10.1001/jamaophthalmol.2021.6173

9. Flaxel Christina J, Flaxel Christina J, Adelman Ron A, Bailey Steven T, Fawzi Amani, Lim Jennifer I, et al. Diabetic Retinopathy Preferred Practice Pattern. San Francisco, CA 94120-7424 [Internet]. Ophthalmology. 2022; 127(1):66-145. DOI: 10.1016/j.ophtha.2019.09.025

10. Zur D, Iglicki M, Busch C, Invernizzi A, Mariussi M, Loewenstein A. OCT Biomarkers as Functional Outcome Predictors in Diabetic Macular Edema Treated with Dexamethasone Implant [Internet]. Ophthalmology. 2018; 125(2):267-75. DOI: 10.1016/j.ophtha.2017.08.031

11. Gu Z, Xi T, Zhang C, Yang G. Optical coherence tomography classifications of diabetic macular edema and response to aflibercept: One-year follow-up outcomes in a Chinese population [Internet]. Medicine. 2023; 102(4):e32815. DOI: 10.1097/MD.0000000000032815

12. Hernández-Da Mota Sergio E, Béjar-Cornejo Francisco, Lima-Gómez Virgilio, Rodríguez-Ayala Ernesto. Autofluorescencia retiniana en la evaluación de la respuesta al tratamiento del edema macular diabético [Internet]. Gac Méd Méx. 2021; 157(4):411-7. DOI: 10.24875/gmm.20000844

13. Barriga-Salaverry Guillermo. Biomarcadores tomográficos en el edema macular diabético [Internet]. Rev Med Hered. 2022; 33(1):56-63. DOI: 10.20453/rmh.v33i1.4170

14. Jiménez-Sierra J M, Cano-Hidalgo R, Flores-Peredo V, Fromow-Guerra J, García-Aguirre G, García-Franco R, et al. Primer consenso nacional de edema macular diabético [Internet]. Rev mex oftalmol. 2021; 95(Suppl 1):1-118. DOI: 10.24875/rmo.m21000206

15. Frizziero L, Midena G, Danieli L, Torresin T, Perfetto A, Parrozzani R, et al. Hyperreflective Retinal Foci (HRF): Definition and Role of an Invaluable OCT Sign [Internet]. Journal of Clinical Medicine. 2025; 14(9):3021. DOI: 10.3390/jcm14093021

16. Lazăr AS, Stanca HT, Tăbăcaru B, Danielescu C, Munteanu M, Stanca S. Quantitative Parameters Relevant for Diabetic Macular Edema Evaluation by Optical Coherence Tomography [Internet]. Angiography Medicina. 2023; 59(6):1120. DOI: 10.3390/medicina59061120

17. Di-Luciano A, Lam W-C, Velasque L, Kenstelman E, Torres RM, Alvarado-Villacorta R, et al. Disorganization of the inner retinal layers in diabetic macular edema: systematic review [Internet]. Rev brasoftalmol. 2022; 81:e0027. DOI: 10.37039/1982.8551.20220027

18. Mehta MT, Edmund MD, Lee MD, Dedania M, Yasha MD. Imaging Biomarkers in Diabetic Retinopathy and Diabetic Macular Edema [Internet]. Int Ophthalmol Clin. 2019; 59(1):241-62. DOI: 10.1097/IIO.0000000000000249

19. Wang P, Hu Z, Hou M, Norman PA, Chin EK, Almeida DR. Relationship Between Macular Thickness and Visual Acuity in the Treatment of Diabetic Macular Edema With Anti-VEGF Therapy: Systematic Review [Internet]. J Vitreoretin Dis. 2022; 18;7(1):57-64. DOI: 10.1177/24741264221138722

20. Yoon K, Kim ES, Yu SY, Kim K. Clinical Characteristics and Long-term Outcomes in Diabetic Macular Edema Patients: With or without Additional Injection Following Ranibizumab Loading [Internet]. Korean J Ophthalmol. 2022; 36(5):398-406. DOI: 10.3341/kjo. .2022.0086

21. Chang HH, Chi SC, Chen SJ, Tai-Chi L. Impact of Aflibercept vs Dexamethasone Treatment on Epiretinal Membrane Formation in Eyes with Diabetic Macular Edema [Internet]. 2024;13(12):3149-59. DOI: 10.1007/s40123-024-01057-z

Downloads

Published

2025-09-05

How to Cite

1.
Rawhi Salem M, Ramos López M, Hormigó Puertas IF. Tomographic characteristics of the vitreomacular interface in diabetic macular edema. Rev Cubana Med Milit [Internet]. 2025 Sep. 5 [cited 2025 Sep. 10];54(3):e025076771. Available from: https://revmedmilitar.sld.cu/index.php/mil/article/view/76771

Issue

Vol. 54 No. 3 (2025): July - September (In Progress)

Section

Clinical Practice Article

License

Copyright (c) 2025 Mohammed Rawhi Salem, Meisy Ramos López, Iraisi Francisca Hormigó Puertas

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Authors who have publications with this Journal accept the following terms:

  • The authors will retain their copyright and guarantee the Journal the right of first publication of their work, which will simultaneously be subject to the Creative Commons Attribution License. The content presented here can be shared, copied and redistributed in any medium or format; Can be adapted, remixed, transformed or created from the material, using the following terms: Attribution (giving appropriate credit to the work, providing a link to the license, and indicating if changes have been made); non-commercial (you cannot use the material for commercial purposes) and share-alike (if you remix, transform or create new material from this work, you can distribute your contribution as long as you use the same license as the original work).
  • The authors may adopt other non-exclusive license agreements for the distribution of the published version of the work (for example: depositing it in an institutional electronic archive or publishing it in a monographic volume) as long as the initial publication in this Journal is indicated.
  • Authors are allowed and recommended to disseminate their work through the Internet (e.g., in institutional electronic archives or on their website) before and during the submission process, which can produce interesting exchanges and increase citations. of the published work.